![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Background. The natural history and the possible changes of celiac disease (CD) prevalence over time are still unclear.
Objectives. 1) To establish whether loss of tolerance to gluten may occur at any age; 2) to investigate possible changes of CD prevalence over time; and 3) to investigate CD-related co-morbidities.
Methods. We analyzed 3,511 subjects with matched samples from 1974 (CLUE I) and 1989 (CLUE II). To avoid a selection bias regarding survival, we also screened 840 CLUE I participants who deceased after the 1974 survey.
Outcome measure. CD autoimmunity (positivity to auto-antibodies) over time.
Results. CD autoimmunity was detected in seven subjects in 1974 (prevalence 1:501) and in an additional nine subjects in 1989 (prevalence 1:219). Two cases of CD autoimmunity were found among the 840 subjects deceased after CLUE I. Compared to controls, untreated CD subjects showed increased incidence of osteoporosis and associated autoimmune disorders, but they did not reach statistical significance.
Conclusions. During a 15-year period CD prevalence increased 2-fold in the CLUE cohort and 5-fold overall in the US since 1974. The CLUE study demonstrated that this increase was due to an increasing number of subjects that lost the immunological tolerance to gluten in their adulthood.
Acknowledgments
This paper was partially supported by the Center for Celiac Research, University of Maryland School of Medicine, Baltimore, MD, USA, Quest Diagnostics Incorporated, San Juan Capistrano, CA, USA, Phadia GmbH, Freiburg, Germany, Schär USA Inc., Lyndhurst, NJ, USA, and BioDiagene, Palermo, Italy.
Declaration of interest: C. Catassi has received research grants and honorariums from the following companies: Schär Italy, Meran, Italy, and A. Menarini Diagnostics, Florence, Italy. A. Fasano has received research grants and honorariums from Quest Diagnostics Incorporated, San Juan Capistrano, CA, USA, Phadia GmbH, Freiburg, Germany, Schär USA Inc., Lyndhurst, NJ, USA, and BioDiagene, Palermo, Italy, and has stock options in Alba Therapeutics Corporation. The remaining authors declare no conflicts of interest.